KRAS and neoplasm: Taken together, research efforts of the past have clarified that oncogenic KRAS-signaling is capable of inhibiting or modulating immune responses on various levels in order to dampen or even completely silence anti-tumor immune responses at different stages of the cancer-immunity cycle and enable unchecked tumor growth.